X0609 4 2026-09-15 0001438533 Travere Therapeutics, Inc. TVTX 0001789617 Heerma Peter false C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 false true false false EVP, CHIEF COMMERCIAL OFFICER 1 Common Stock 2026-09-15 4 M 0 39283 26.88 A 181349 D Common Stock 2026-09-15 4 M 0 1381 22.40 A 182730 D Common Stock 2026-09-15 4 M 0 36526 8.93 A 219256 D Common Stock 2026-09-15 4 S 0 71938 62.0517 D 147318 D Common Stock 2026-09-15 4 S 0 27421 62.5936 D 119897 D Common Stock 2026-09-15 4 S 0 1400 63.6521 D 118497 D Common Stock 2026-09-15 4 S 0 1431 65.3093 D 117066 D Common Stock 2026-09-16 4 M 0 100000 11.25 A 217066 D Common Stock 2026-09-16 4 M 0 55000 15.46 A 272066 D Common Stock 2026-09-16 4 M 0 17717 26.88 A 289783 D Common Stock 2026-09-16 4 S 0 93604 63.2471 D 196179 D Common Stock 2026-09-16 4 S 0 79113 63.6546 D 117066 D Common Stock 2026-09-17 4 M 0 8282 22.40 A 125348 D Common Stock 2026-09-17 4 S 0 8282 65.0709 D 117066 D Employee stock option (right to buy) 26.88 2026-09-15 4 M 0 39283 0 D 2031-01-21 Common Stock 39283 18217 D Employee stock option (right to buy) 22.40 2026-09-15 4 M 0 1381 0 D 2033-01-31 Common Stock 1381 53119 D Employee stock option (right to buy) 8.93 2026-09-15 4 M 0 36526 0 D 2034-01-31 Common Stock 36526 28474 D Employee stock option (right to buy) 11.25 2026-09-16 4 M 0 100000 0 D 2029-10-01 Common Stock 100000 0 D Employee stock option (right to buy) 15.46 2026-09-16 4 M 0 55000 0 D 2030-01-31 Common Stock 55000 0 D Employee stock option (right to buy) 26.88 2026-09-16 4 M 0 17717 0 D 2031-01-21 Common Stock 17717 500 D Employee stock option (right to buy) 22.40 2026-09-17 4 M 0 8282 0 D 2033-01-31 Common Stock 8282 44837 D Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $62.0517, and the range of prices were between $61.43 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $62.5936, and the range of prices were between $62.43 and $63.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-09-17